EIF2AK3 and hepatocellular carcinoma: Five out of 24 cases that could be analyzed (20.8%) showed immunostaining for nuclear pERK and only 1 (5.3%) control presented a weak (10%) immunostaining for pERK, suggesting that activation of MAPK pathway was more frequent in HCC patients compared to the control group.